CAIRE Inc. has announced the acquisition of Spirosure, Inc. Spirosure is a California-based developer and manufacturer of innovative technology for measuring Fractional Exhaled Nitric Oxide (FeNO), a key indicator of allergic inflammation in asthmatic patients. It is estimated that asthma affects more than 300 million individuals worldwide and recent Global […]

Spirosure Inc. announced that it has made an FDA 510(k) submission seeking U.S. clearance for its Fenom PRO Point-of-Care Breathalyzer, which was launched in September at the world’s largest meeting for respiratory physicians, scientists and allied health professionals: the European Respiratory Society (ERS) International Congress 2017. Fenom PRO is CE […]